Welcome to our Corporate client solution
Your IP is registered with the company mentioned above and provides access to Life Science Sweden.
Bioteknikbolaget Asarina Pharma har inlett en fas IIa-studie med läkemedelskandidaten Sepranolon vid Tourettes syndrom.